The Journal of Travel Medicine will consider publication of manuscripts that deal with the broad field of travel medicine and migration health and have not been published, simultaneously submitted, or already accepted for publication elsewhere. This does not preclude consideration of a complete report that follows publication of preliminary findings elsewhere.
All manuscripts are submitted and reviewed via the journal’s web-based manuscript submission system (http://mc.manuscriptcentral.com/jtm). New authors should create an account prior to submitting a manuscript for consideration. Questions about submitting to the journal should be sent to the editorial office at email@example.com.
Manuscripts should be identified as submissions to one of the following categories:
All submissions to the journal are initially reviewed by the Editor. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the Journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process.
Manuscripts that are not instantly rejected are sent out for peer review, usually to two independent reviewers. Based on the feedback from these reviewers and the Editor’s judgment a decision is given on the manuscript. The average time from submission to first decision is 3-4 weeks.
If a paper is not acceptable in its present form, we will pass on suggestions for revisions to the author.
Language editing, particularly if English is not your first language, can be used to ensure that the academic content of your paper is fully understood by the journal editors and reviewers. Please note that edited manuscripts will still need to undergo peer-review by the journal.
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
Manuscripts submitted to JTM may be screened with iThenticate anti-plagiarism software in an attempt to detect and prevent plagiarism. Any manuscript may be screened, especially if there is reason to suppose part or all of the text has been previously published. Prior to final acceptance any manuscript that has not already been screened will be put through iThenticate. More information about iThenticate can be found http://www.ithenticate.com/
In order to reproduce any third party material, including tables, figures, or images, in an article authors must obtain permission from the copyright holder and be compliant with any requirements the copyright holder may have pertaining to this reuse. When seeking to reproduce any kind of third party material authors should request the following:
- non-exclusive rights to reproduce the material in the specified article and journal;
- print and electronic rights, preferably for use in any form or medium;
- the right to use the material for the life of the work; and
- world-wide English-language rights. If rights for all languages can be secured, this is preferable.
It is particularly important to clear permission for use in both the online and any possible print versions of the journal, and we are not able to accept permissions which carry a time limit because we retain journal articles as part of our online journal archive.
Further guidelines on clearing permissions can be found here.
If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:
Title of content. Author, Original publication, year of original publication, by permission of [rights holder]. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.
Authors who wish to re-use material previously published in Journal of Travel Medicine should refer to the instructions at http://www.oxfordjournals.org/access_purchase/rights_permissions_jtm.html.
For the journal’s self-archiving policy, please go to http://www.oxfordjournals.org/en/access-purchase/rights-and-permissions/self-archiving-policyb.html
Journal of Travel Medicine authors have the option to publish their paper under the Oxford Open initiative; whereby, for a charge, their paper will be made freely available online immediately upon publication.
After your manuscript is accepted, the corresponding author will be required to accept a mandatory licence to publish agreement. As part of the licensing process you will be asked to indicate whether or not you wish to pay for open access. If you do not select the open access option, your paper will be published with standard subscription-based access and you will not be charged.
RCUK/Wellcome Trust/COAF funded authors publishing in Journal of Travel Medicine can use the Creative Commons Attribution licence (CC-BY) for their articles. All other authors may use the following licences:
- Creative Commons Attribution Non-Commercial licence (CC-BY-NC)
Please click here for more information about Creative Commons licences.
The Open Access charges are as follows.
ALL ARTICLE TYPES EXCEPT CORRESPONDENCE – optional Oxford Open charges for CC-BY:
- Regular charge: £2000/ $3200 / €2600
- Reduced Rate Developing country charge*: £1000/ $1600 / €1300
- Free Developing country charge*: £0 /$0 / €0
ALL ARTICLE TYPES EXCEPT CORRESPONDENCE – optional Oxford Open charges for CC-BY-NC:
- Regular charge: £1750/ $2800 / €2275
- Reduced Rate Developing country charge*: £875/ $1400 / €1138
- Free Developing country charge*: £0 /$0 / €0
CORRESPONDENCE – optional Oxford Open charges for CC-BY:
- Regular charge - £1000 / $1600 / €1300
- Reduced Rate Developing country charge** - £500 / $800 / €750
- Free Developing country charge** - £0 / $0 / €0
CORRESPONDENCE – optional Oxford Open charges for CC-BY-NC:
- Regular charge: £875/ $1400 / €1138
- Reduced Rate Developing country charge*: £438/ $701 / €570
- Free Developing country charge** - £0 / $0 / €0
*Visit our developing countries page (click here for a list of qualifying countries).
You can pay Open Access charges using our Author Services site. This will enable you to pay online with a credit/debit card, or request an invoice by email or post.
Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your institution, and ensure your account for your own local VAT correctly.
Crossref Funding Data Registry
In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about the CHORUS initiative please click here.
Each manuscript should be submitted electronically as a Microsoft Word document, including all tables on separate pages following the reference list, together with a full list of numbered figure legends. Figures should be submitted as separate documents, each bearing a figure number, and not embedded in Word or PowerPoint.
Create the text, preferably in Times New Roman, 12 pt, on standard size pages, double-spaced throughout with margins of at least 2.5 cm (1 in.). Do not right-justify margins and do not use a hard line return except when ending a paragraph. All pages should be numbered consecutively in the right upper corner, beginning with the title page.
On the title page, include the following: the title of the paper; a running title (≤ 69 letters and spaces); the first name, middle initial, and last name and the highest academic rank attained by each author; the name of the department and institution for each author; footnotes indicating the meetings at which the paper has been presented, if any; grants or other financial support, if any; and the name and address of the person to whom correspondences and reprint requests should be addressed.
Abstracts are required for original articles, review articles and letters. Original articles and review articles require a structured abstract of 250 to 300 words with the following headings: Background, Methods, Results, and Conclusions. Brief communications require a non-structured abstract of 50 words maximum. Use a separate page to provide an abstract.
Usually the text is structured as mentioned under Abstract (see above) for original articles. Whenever research involves human subjects, authors must state in the Methods section that the project had obtained approval from a recognized ethics committee. For other contributions the structure is not regulated, but always keep the text as concise as possible.
All tables and figures must be cited in text and numbered in order of citation.
Each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. Please include the following in your submitted manuscripts:
Author contributions should be stated in full (i.e. who did what on the paper).
Sources of funding
Details of all funding sources for the work in question should be given in a separate section entitled ‘Funding’. This should appear before the ‘Acknowledgements’ section.
The following rules should be followed:
- The sentence should begin: ‘This work was supported by …’
- The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 'NCI at NIH’ (full RIN-approved list of UK funding agencies)
- Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
- Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
- Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].
Oxford Journals will deposit all NIH-funded articles in PubMed Central. Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above.
- Conflict of Interest/Disclosure
Any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition – should be disclosed. For further information see FAQ.
If there are none, the disclosure should say: ‘The authors have declared no conflicts of interest.' If one or a few authors have a conflict to disclose, further to that statement, there should be an additional statement for those remaining authors who do not have any, e.g. ‘All remaining authors have declared no conflicts of interest.’
All references must be cited by number in the text, tables, or figure legends. References should be numbered and typed double-spaced in the order of their occurrence in the manuscript. List all authors when there are four or fewer; otherwise, list the first three followed by ‘et al.’ References to journals should include (in this order) authors’ names with initials, article title, journal name (Index Medicus abbreviations), year, volume number, and inclusive page numbers.
- Example: DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. N Engl J Med 1993; 328:1821–1827.
References to books should include (in this order) authors’ names with initials, chapter title, editors’ name and initials, book title and edition, city, publisher, year of publication, and inclusive page numbers.
- Example: Goepp JG, Hirschhorn B. Fluid therapy of diarrhea. Part I: developing countries. In: Walker WA, Durie PR, Hamilton JR, et al., eds. Pediatric gastrointestinal disease. Pathophysiology, diagnosis, management. Vol 2. Philadelphia: BC Decker, 1991:1561–1566.
- Example: Bayless TM, ed. Current therapy in gastroenterology and liver disease. 3rd Ed. Philadelphia: BC Decker, 1990.
The author is responsible for the accuracy of the references. Manuscripts accepted but not yet published should be designated ‘in press’. Unpublished information in manuscripts submitted for publication should be cited in the text (not on the reference list) by name(s) of author(s) and ‘personal communication’ and should include the date of the communication.
Tables should be prepared in Microsoft Word, not as images. They should be double-spaced, each on a separate page, including a brief title and all headings in place, and be placed at the end of the manuscript, following the reference list.
Figures must NOT be embedded in Microsoft Word or PowerPoint as quality and accuracy cannot be guaranteed. Line drawings should be saved as TIF, JPG, or EPS files at 600 dpi at 13 cm (5 in.) in width (flow charts must not exceed 18 cm [7 in.] in width). Each figure should bear a figure number corresponding to a legend listed in the manuscript. Include the original magnification of photomicrographs, and identify stains used in preparations.
For information on how to submit figure files, please see the Oxford Journals page on figures http://oxfordjournals.org/en/authors/figures.html. You can also send queries about figure files to firstname.lastname@example.org.
Supplementary Data can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supplementary data might include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related non-essential multimedia files. Supplementary Data should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior to publication; for these reasons, authors should provide any Supplementary Data in the desired final format.
A cover letter should include the following:
- Identification of one person (with address, e-mail address, telephone) as corresponding author, who is responsible for all communication.
- A statement that the manuscript has been seen and approved by all authors, who accept full responsibility for the content. It should also indicate that the authors had full access to the data and their analysis, as well as drafting the article or editing an author’s draft.
- JTM supports the International Committee of Medical Journal Editors (ICMJE) in calling for the registration of all clinical trials at their inception. In accordance with this, authors of clinical trials are required to register their trial with one of the ICMJE recognised trial registries - click here <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>. Upon submission, authors of trials are asked to provide evidence in the form of a trial registry number, the date of trial registration and the date of the first patient enrolment. These two dates and the unique identifier will be published at the end of the abstract in accord with ICMJE recommendations.
Trials that are submitted without this information will not enter the review process until missing information is provided. Unregistered trials will not be considered for review.